Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 234

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Targeting the BRAF V600E Mutation in Multiple Myeloma

Andrulis, Mindaugas, Lehners, Nicola, Capper, David, Penzel, Roland, Heining, Christoph, Huellein, Jennifer, Zenz, Thorsten, von Deimling, Andreas, Schirmacher, Peter, Ho, Anthony D., Goldschmidt, Hartmut, Neben, Kai, Raab, Marc S. · 2013 · Cancer Discovery

Abstract

In multiple myeloma, there has been little progress in the specific therapeutic targeting of oncogenic mutations. Whole-genome sequencing data have recently revealed that a subset of patients carry an activating mutation (V600E) in the BRAF kinase. To uncover the clinical relevance of this mutation in multiple myeloma, we correlated the mutation status in primary tumor samples from 379 patients with myeloma with disease outcome. We found a significantly higher incidence of extramedullary disease and a shorter overall survival in mutation carriers when compared with controls. Most importantly, we report on a patient with confirmed BRAF V600E mutation and relapsed myeloma with extensive extramedullary disease, refractory to all approved therapeutic options, who has rapidly and durably responded to low doses of the mutation-specific BRAF inhibitor vermurafenib. Collectively, we provide evidence for the development of the BRAF V600E mutation in the context of clonal evolution and describe the prognostic and therapeutic relevance of this targetable mutation. Significance: This is the first evidence of the clinical and therapeutic relevance of BRAF V600E mutations in multiple myeloma, proving the principle of specific inhibition of driver mutations in this disease. Cancer Discov; 3(8); 862–9. ©2013 AACR. See related commentary by O'Donnell and Raje, p. 840 This article is highlighted in the In This Issue feature, p. 826

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0014

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 234

Metadata

Authors
Andrulis, M., Lehners, N., Capper, D., Penzel, R., Heining, C., Huellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A. D., Goldschmidt, H., Neben, K., & Raab, M. S.
Venue
Cancer Discovery
Published
2013-08-01
Volume
3
Issue
8
Pages
862-869
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2158833600
Cited by
234
References
7
FWCI
18.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the BRAF V600E Mutation in Multiple Myeloma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0014
The paper
Andrulis, M., Lehners, N., Capper, D., Penzel, R., Heining, C., Huellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A. D., Goldschmidt, H., Neben, K., & Raab, M. S. (2013). Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.